INTRODUCTION
Incorporation techniques of lipophilic drug active ingredients with poor aqueous solubility are used particularly in pharmaceutical technology for drug delivery design. Advantages of encapsulation include enhanced stability of labile drugs, controlled drug release and improved drug bioavailability.
agents by direct exposure to UV light. 2 Fluconazole (FZ) is a triazole antifungal agent (Figure 1 ) with poor aqueous solubility administered either orally or intravenously. 3 It is used in the treatment of oropharyngeal and esophageal candidiasis, urinary tract infections, pneumonia, peritonitis and serious systemic candidal infections. 4, 5 Adverse effects of FZ were reported to be related to the gastro-intestinal tract including abdominal pain, diarrhea, flatulence, nausea and vomiting. Other side effects associated with FZ are headache, dizziness, leucopenia, thrombocytopenia, hyperlipidemias, and raise in liver enzyme values. Serious hepatotoxicity was also reported while anaphylaxis, angioedema and skin reaction were rarely reported. 5 Dermal delivery by topical preparations such as creams, gels and lotions are limited due to the b characteristics of Stratum corneum. This limitation hinders the drug deposition and leads to rela poor stability of active agents by direct exposure to UV light. 2 Fluconazole (FZ) is a triazole antifungal agent (Figure 1 ) with poor aqueous solubility adminis either orally or intravenously. 3 It is used in the treatment of oropharyngeal and esophageal candid urinary tract infections, pneumonia, peritonitis and serious systemic candidal infections. 4, 5 Ad effects of FZ were reported to be related to the gastro-intestinal tract including abdominal pain, diar flatulence, nausea and vomiting. Other side effects associated with FZ are headache, dizz leucopenia, thrombocytopenia, hyperlipidemias, and raise in liver enzyme values. Se hepatotoxicity was also reported while anaphylaxis, angioedema and skin reaction were rarely repo with several advantages such as the possibility of targetting the drug to the desired site controlled/sustained pattern. In this manner, therapeutic efficacy may be increased while reducin side effects. 6, 7 Some antifungal agents have been entrapped in particulate delivery system and prom results were observed in animal models and clinical therapy. These studies include mainly the po drugs, represented by amphotericin B and nystatin. 7, 8 There are many studies regarding azole antif particulate drug delivery systems. Several classes of antifungal agents can be used in the treatment of candidiasis. However, among the factors influencing the efficacy of therapy is the immunity of the patient. Clinical failure following therapy may exist in patients with advanced immunodeficiency. In such cases, high doses of drugs or the use of multiple agents may be required thereby increasing the risk of serious side effects. To avoid this complication, entrapment of antifungal agents like FZ in a particulate delivery system can be used with several advantages such as the possibility of targetting the drug to the desired site in a controlled/sustained pattern. In this manner, therapeutic efficacy may be increased while reducing the side effects. 6, 7 Some antifungal agents have been entrapped in particulate delivery system and promising results were observed in animal models and clinical therapy. These studies include mainly the polyene drugs, represented by amphotericin B and nystatin. 7, 8 There are many studies regarding azole antifungal particulate drug delivery systems. 9, 10 Chitosan gained an increasing interest as a pharmaceutical excipient. 11 Chitosan is a hydrophilic, biocompatible and biodegradable polymer with low toxicity. It was investigated extensively for pharmaceutical and medical purposes including incorporation of therapeutic agents, proteins, enzymes, DNA and cells, formulation for oral vaccines and stabilization of liposomes. 12, 13 Among the pharmaceutical applications of chitosan are the use as a vehicle for directly compressed tablets, as a disintegrant, a binder, a granulating agent in ground mixtures, as a drug carrier for sustained release preparations as well as a cogrinding diluent for the enhancement of dissolution rate and bioavailability of water insoluble drugs. 14 Furthermore, chitosan has mucoadhesive properties due to the molecular attraction formed by electrostatic interactions between positively charged chitosan and negatively charged mucosal surfaces. 15, 16 Spray drying represents a single-step, cheap, continuous and scalable process dedicated for converting liquids into dry, free-flowing powders which enables the production of particles with controlled size and morphological aspects.
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Spray drying also eliminates the addition of crosslinking agent minimizes the swelling of chitosan based nanoparticles. 12 Therefore, spray drying technology was utilized in this study for the formulation of cationic nanoparticles using advantages of the method.
The objective of this study was to formulate chitosan-based cationic particulate systems containing FZ with high encapsulation efficiency and prolonged effect for reducing side effects and improving its stability. Chitosan nanoparticles were prepared by the spray-drying technique for topical skin fungal infections. Particle size, particle size distribution and thermal behaviour of the polymeric lattice were analyzed. Drug loading and release of the incorporated FZ were analyzed using a validated HPLC method.
METHODOLOGY

Materials
FZ was a kind gift from Bilim İlaç (Türkiye). Chitosan was purchased from Fluka Chemicals (Germany), acetic acid from Sigma-Aldrich (Germany) and ethanol from Carlo Erba (Italy). Sodium chloride, methanol and acetonitrile were the products of Merck (Germany).
Preparation of chitosan nanoparticles
Formulations were prepared using Mini Spray Dryer (B-190, BUCHI, Switzerland). The spray dryer was connected to the Inert Loop B-295 (Buchi Labortechnik AG, Switzerland) due to the organic solvent. Carbon dioxide gas was used at a flow rate of 120 L.min -1 . The residual oxygen level in the system was controlled below 4%.
When preparing particulate systems by spray-drying method, it has to be kept in the mind that production parameters such as size of nozzle, feeding pump rate, inlet temperature and compressed air flow rate, affect the particle size. 12, 18 It was reported that smaller particles are formed with lower feeding pump rate and smaller nozzle size. In addition, smaller particles are formed with greater volume of air input where particle size is not dependent inlet temperature in the range of 120-180°C. 12 Briefly, FZ and chitosan were dissolved in 96% (v/v) ethanol and 2% (v/v) acetic acid solutions, respectively. The solutions were mixed and homogenized at 1500 rpm for 3 hours. The final clear solution was then spray-dried with an inlet temperature of 145ºC ± 1°C and an outlet temperature of 50ºC ± 3°C. White dry powders were obtained and kept in tightly closed vials at room temperature until being analyzed. The placebo formulation was prepared as described above without the addition of FZ. These were bare, empty nanoparticles.
Composition of the formulations was kept as simple as possible (Table 1) . 
Characterization of chitosan nanoparticles
Particle size and zeta potential analyses
Particle size, particle size distribution (PDI) and zeta potential measurements of the formulations prepared were performed on freshly prepared samples using Malvern Nano ZS (Zetasizer Nano Series, Worcestershire, UK). Samples of all formulations were dispersed in double distilled water (adjusted to a constant conductivity of 50 μS.cm -1 using 0.9% NaCl) just prior to analyses. All analyses were repeated in triplicate at 25°C ± 2°C.
Morphology
The particle shape and surface characteristics of the freshly prepared nanoparticle formulations and FZ were investigated by scanning electron microscope (SEM) (HITACHI TM3030Plus Tabletop Microscope, Japan) at 25°C ± 2°C. Samples were coated with a thin layer gold under argon to avoid charging under the electron beam.
Thermal analysis
Thermal behaviors and the interactions between FZ and chitosan were analyzed using differential scanning calorimetry (DSC) (DSC-60, Shimadzu Scientic Instruments, Columbia, MI, USA). In DSC analyses, the heating rate of 10ºC. min -1 was employed in the temperature range of 50ºC-200ºC. Analyses were carried out under nitrogen with a scan rate of 5 K.min -1
.
X-ray diffractometry analysis
Dry powder X-ray diffractometry (XRD) analyses were performed using RIKA-GU D/Max-3C (Japan). The XRD analysis range was 2°C-40°C over 2θ with 2°C min -1 scanning rate, with 40 kV voltage and current intensity level of 30 mA.
Pure FZ and placebo formulation were also analyzed and those XRD spectra were used as references in evaluating the chitosan nanoparticles containing FZ.
Determination of FZ content of chitosan nanoparticles
For the quantification of FZ incorporated into FZ formulations, accurately weighed (5 mg) formulations were dissolved in acetic acid (2%, v/v) solution and ethanol (5 mL, 4:1) mixture and agitated at 4000 rpm for 3 min.1 mL of supernatant was collected. Drug content of nanoparticles was determined using the reversed-phase HPLC method equipped with a pump (LC 10-AD), a UV detector (SPD-20A), a data station (Shimadzu, Japan) and C 18 column (250 mm x 4.6 mm i.d. and 5 μm particle size). The mobile phase consisting of distilled water (tetrabutylammonium hydrogen sulfate): acetonitrile (75:25, v/v) was degassed prior to the analysis. The flow rate was 1 mL.min -1 with an injection volume of 25 μL. The oven temperature was adjusted to 30ºC ± 1ºC and FZ was monitored at 223 nm.
In vitro release studies of FZ from chitosan nanoparticles
In vitro release studies were performed using Franz diffusion cells. 2 The diffusion cells were thermoregulated with a water jacket at 32º C. Polypropylene membrane was placed on a Franz diffusion cell after keeping it 20 minutes in the donor compartment. The receptor chamber was filled with distilled water. 1000 μg of formulation was applied to the donor compartment. 0.5 mL aliquots were withdrawn from the receptor compartment at specific time intervals. The amounts withdrawn were replaced by the fresh distilled water. The amount of FZ in aliquots was analyzed by a validated HPLC method and release profiles were obtained.
RESULTS AND DISCUSSION
Preparation of chitosan nanoparticles
In this study, spray-drying method was successfully used to prepare chitosan nanoparticles since it does not involve toilsome procedures and avoids the use of harsh cross-linking agents and organic solvents which might possibly trigger chemical reactions with the active agent.
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Characterization of chitosan nanoparticles
Particle size and zeta potential measurements
Particle size is one of the important physical properties of colloidal systems. Particle size distribution of the formulation is especially significant in the physical stability and activity of colloidal systems. 20 It was also found that the size of nanoparticles play an important role in their adhesion to and interaction with the biological cells. 21 Particle sizes of formulations were found to be 552.50 ± 10.30 nm and 648.25 ± 8.81 nm for C-FZ-1 and C-FZ-2, respectively ( Table 2 ). It was found that decrease in the amount of FZ in formulations was in parallel with the relative decrease in average particle size. The acceptable value for PDI is 0.05-0.7; values greater than 0.7 indicate very broad size distribution and probably no suitability for dynamic light scattering technique. 22 As shown in Table 2 , acceptable PDI values were obtained for all batches. Also, PDI data showed that the homogeneity increased with the addition of FZ into the formulations. 23 Zeta potential of nanoparticles is commonly used to characterize the surface property of nanoparticles. Results showed that zeta potentials measured were 38.4 ± 0.2 mV and 40.4 ± 2.3 mV for C-FZ-1 and C-FZ-2, respectively, which may be attributed to the positive charges on polymeric matrices indicating adequate physical stability. Cationic chitosan nanoparticles with mucoadhesive properties may interact with the negatively charged of skin and open up the tight junctions of epithelial cells to allow the paracellular transport pathway resulting in an increase in bioavailability of the active agents.
16,21
Morphology SEM images of pure FZ and formulations were demonstrated in Figure 2 . SEM images showed that all formulations prepared were nearly in spherical shape while some of the spheres reminded the collapsed balloons with smooth surfaces. Crystalline structure of FZ was not observed in the formulations indicating successful incorporation of FZ into the polymeric matrices. 
Thermal analysis
DSC was in order to determine the incorporation of FZ into the polymeric network and also the status of polymer and active agent after spray-drying process.
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The thermogram of FZ shows the simple thermal behaviour of the drug (Figure 3a) . The sharp endothermal peak the observed at 142.66ºC is the first order solid-liquid phase transition corresponding to the melting of the drug. 3 Placebo formulation (Figure 3b ) was characterized by its amorphous state since no endothermic peak was observed. In the DSC thermogram of formulations, sharp peak belonging to FZ was not observed (Figure 3c ). There may be two explanations of this peak disappearance. First explanation is the molecular incorporation of FZ into chitosan nanoparticles. When FZ was molecularly dispersed within the polymeric matrix resulting in a solid solution, the endothermal peak of FZ has 
Thermal analysis
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The thermogram of FZ shows the simple thermal behaviour of the drug (Figure 3a). The sharp endothermal peak the observed at 142.66ºC is the first order solid-liquid phase transition corresponding to the melting of the drug.
tions, sharp peak belonging to FZ was not observed (Figure 3c ). There may be two explanations of this peak disappearance. First explanation is the molecular incorporation of FZ into chitosan nanoparticles. When FZ was molecularly dispersed within the polymeric matrix resulting in a solid solution, the endothermal peak of FZ has disappeared. 11, 12, 25 Second explanation is the dilution effect of the polymer network. When the ratio of drug:polymer is so small, the massive amount of polymer shades the endothermal peak of the drug. 26 disappeared. 11, 12, 25 Second explanation is the dilution effect of the polymer network. When the ratio of drug:polymer is so small, the massive amount of polymer shades the endothermal peak of the drug. 
X-ray diffractometry analysis
DSC and XRD play a prominent role in the characterization of polymeric matrices because they are able to provide structural information on the dispersed particles. 27 Therefore, in this study for better evaluation of the crystalline polymeric structure of polymeric particles DSC and XRD analyses were 
DSC and XRD play a prominent role in the characterization of polymeric matrices because they are able to provide structural information on the dispersed particles. 27 Therefore, in this study for better evaluation of the crystalline polymeric structure of polymeric particles DSC and XRD analyses were performed simultaneously.
Dry powder XRD analyses of nanoparticles confirmed the DSC results showing the amorphous state of the polymeric network. XRD patterns of pure FZ, placebo and formulations were demonstrated in Figure 4 . The FZ spectrum shows several sharp diffraction peaks typical of its crystalline state ( Figure  4a ) while placebo and FZ-containing formulations were of amorphous state with no sharp XRD peaks in the spectra (Figure 4b and Figure 4c ). In the patterns of the FZ loaded formulations, peaks corresponding to FZ disappeared, indicating that dispersion in an amorphous form. 13, 26 in the spectra (Figure 4b and Figure 4c ). In the patterns of the FZ loaded formulations, peak corresponding to FZ disappeared, indicating that dispersion in an amorphous form. 
Determination of FZ content of formulations
A validated HPLC method used for the determination of FZ demonstrated that the incorporatio efficiency of FZ in formulations were found to be 8.99 ± 0.54 % and 12.04 ± 2.05 % (mean ± SE), fo C-FZ-1 and C-FZ-2, respectively. It is evident from the data that incorporation efficiency was affecte by the drug: polymer ratio. The results revealed that the incorporation efficiency of formulations wa increased with increasing concentration of the active agent in the formulations. 21 Relatively lo incorporation efficiency of nanoparticles prepared may be attributed to the spray-drying parameters suc as nozzle diameter, spraying rate or viscosity of the spraying solution.
In vitro drug release
In vitro dissolution test plays an important role in drug formulation development and quality control.
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Determination of FZ content of formulations
A validated HPLC method used for the determination of FZ demonstrated that the incorporation efficiency of FZ in formulations were found to be 8.99 ± 0.54 % and 12.04 ± 2.05 % (mean ± SE), for C-FZ-1 and C-FZ-2, respectively. It is evident from the data that incorporation efficiency was affected by the drug: polymer ratio. The results revealed that the incorporation efficiency of formulations was increased with increasing concentration of the active agent in the formulations. 21 Relatively low incorporation efficiency of nanoparticles prepared may be attributed to the spray-drying parameters such as nozzle diameter, spraying rate or viscosity of the spraying solution.
In vitro drug release
In vitro dissolution test plays an important role in drug formulation development and quality control. It can be used not only primary tool to observe the consistency and stability of drug products but also as a relatively rapid and inexpensive process to estimate in vivo absorption of a drug formulation.
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The in vitro release profile of FZ from formulations were shown in Figure 5. Franz diffusion cell analyses results showed that the release of FZ from formulations were 26.12 % and 29.52 % at the end of 180 minutes for C-FZ-1 and C-FZ-2, respectively. Flux (J) and permeation coefficient (k p ) values were determined using the slope of the steady-state portion of the amount of the drug permeated and divided by time. for the C-FZ-1 and C-FZ-2, respectively. The results indicated that the release of FZ from the formulations varied depending on time. FZ was successfully incorporated into chitosan nanoparticles using a spraydrying method. In vitro characteristics of nanoparticles prepared were analyzed to confirm incorporation of FZ into the polymeric structure. When submicron sized with homogenous size distribution and nearly spherical nanoparticles were prepared. DSC and XRD assays confirmed decrease in FZ crystallinity in cationic nanoparticles. Chitosan nanoparticles released FZ for 180 minutes indicative of the extended release of the drug, which will reduce the side effects in treating the infections induced by Candida albicans. With the cationic and mocuadhesive properties of chitosan-based system, nanoparticles will ensure longer residence at the infection site, providing a favorable release profile for the FZ for the dermal delivery.
Conclusively, chitosan nanoparticles may be good alternative for delivery of FZ, which need to be, investigated further using in vivo tests before final decision.
